Clinical Trials

Clinical Trials

  Section Menu

CIMAvax Vaccine

Roswell Park has launched the first clinical trial in the U.S. to study the CIMAvax-EGF ® vaccine, a lung cancer treatment. Learn more about CIMAvax.

A clinical trial is a study designed to evaluate a promising new medical treatment. It includes research done to evaluate new ways to prevent and diagnose and/or treat cancer. At Roswell Park, up to 50% of our patients are eligible to enter clinical trials. Many types of treatment can be tested including:

  • New ways of preventing cancer such as drugs, diet, and/or exercise
  • New drugs to treat cancer
  • New ways to use existing treatment such as surgery or radiation therapy

When clinical trials identify new and effective treatments, these treatments will eventually become the new standard of care that will be offered to future patients. Today’s standard treatments were researched and proven by clinical trials done in the past.

Should I participate in a clinical trial? (Learn more about clinical trials from the NCI.)

Recently Opened Clinical Trials

(CCT-PNK-007-MM-001) A phase 1, multicenter, open-label, safety study of human cord blood derived, culture-expanded, natural killer cell (PNK-007) infusion with subcutaneous recombinant human IL-2 (rhIL-2) following autologous stem cell transplant for...
Principal Investigator:
Ho, Christine M
( SCRX001-006) An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors
Principal Investigator:
Dy, Grace K
"Talking Pictures": An exploratory study of meaning-based social media intervention for Adolescent and Young Adult cancer patients
Principal Investigator:
Beaupin, Lynda K
Direct oral anticoagulants (DOACs) versus LMWH +/- warfarin for VTE in cancer: A randomized effectiveness trial (CANVAS trial)
Principal Investigator:
Levine, Ellis G
An Open Label, Dose-Finding and Proof of Concept Study of the PD-L1 Probody Therapeutic, CX-072, as Monotherapy and in Combination with Yervoy® (Ipilimumab) or with Zelboraf® (Vemurafenib) in Subjects with Advanced or Recurrent Solid Tumors or...
Principal Investigator:
Opyrchal, Mateusz
A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents
Principal Investigator:
Griffiths, Elizabeth A
Study 16-214-01 (Combination): A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 Nivolumab in Subjects with Locally Advanced or Metastatic Solid Tumor Malignancies
Principal Investigator:
Puzanov, Igor